22nd Century Group (NASDAQ:XXII) Trading 2.5% Higher – Time to Buy?

22nd Century Group, Inc (NASDAQ:XXII)’s share price traded up 2.5% during trading on Friday . The stock traded as high as $5.97 and last traded at $5.81. 71,437 shares were traded during mid-day trading, an increase of 193% from the average session volume of 24,344 shares. The stock had previously closed at $5.67.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of 22nd Century Group in a research report on Monday, December 29th. Wall Street Zen raised shares of 22nd Century Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

22nd Century Group Price Performance

The stock has a 50 day moving average price of $12.58 and a two-hundred day moving average price of $21.66. The firm has a market capitalization of $2.96 million, a price-to-earnings ratio of -0.01 and a beta of 1.07.

22nd Century Group (NASDAQ:XXII) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported ($15.90) EPS for the quarter, beating analysts’ consensus estimates of ($251.85) by $235.95. 22nd Century Group had a negative return on equity of 184.33% and a negative net margin of 37.64%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in 22nd Century Group stock. Anson Funds Management LP lifted its holdings in 22nd Century Group, Inc (NASDAQ:XXII) by 197.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 98,212 shares of the biotechnology company’s stock after purchasing an additional 65,174 shares during the period. Anson Funds Management LP owned approximately 1.41% of 22nd Century Group worth $166,000 at the end of the most recent reporting period. 18.06% of the stock is currently owned by institutional investors and hedge funds.

About 22nd Century Group

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.